English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Epithelial ovarian cancer is the fourth most common cause of cancer-related death among women worldwide. Over 220,000 woman are diagnosed with epithelial ovarian cancer every year, with the incidence of the disease estimated to be 5 per 100,000 people.1 According to asymptomatic in early stage disease, over 80% of patients have symptoms even when the disease is widely metastatic to abdominal lumen.2 The overall survival rate of patients with ovarian cancer has improved from 36% to 46% due to taxane and platinum chemotherapies.3 Yet chemotherapeutic agents can cause side effects and are only able to prolong five-year survival rates for patients with an advanced stage of the disease—such as stage IIIC— for a mere 39% of patients.4 New effective treatment is therefore crucial to improve survivability and should be subject to intensive study.

Honokiol and Magnolol Induce Apoptosis and Cell Cycle Arrest in Human Ovarian Cancer Cells